Captopril Inhibits Endothelin-1 Secretion From Endothelial Cells Through Bradykinin

Naoko Momose, Keisuke Fukuo, Shigeto Morimoto, and Toshio Ogihara

Incubation with captopril, an angiotensin I converting enzyme inhibitor, for 24 hours at concentrations up to $10^{-7}$ M inhibited endothelin-1 secretion by endothelial cells. This inhibition of endothelin-1 secretion was reversed by coincubation with $3 \times 10^{-7}$ M $N^\circ$-nitro-L-arginine, an inhibitor of nitric oxide synthesis. Furthermore, captopril enhanced the production of nitric oxide in endothelial cells, suggesting that enhancement of nitric oxide production participates in captopril-induced inhibition of endothelin-1 secretion. Moreover, in the presence of $10^{-4}$ M d-Arg, [Hyp$^3$,Thi$^3$,D-Phe$^7$]-bradykinin, a bradykinin B$_1$ receptor antagonist, captopril did not inhibit but rather stimulated endothelin-1 secretion, whereas bradykinin inhibited endothelin-1 secretion, and this inhibition by bradykinin was reversed by coincubation with $N^\circ$-nitro-L-arginine. In addition, enhancement of nitric oxide production induced by either captopril or bradykinin was inhibited by d-Arg, [Hyp$^3$,Thi$^3$,D-Phe$^7$]-bradykinin. Although $10^{-4}$ M des-Arg$^9$-[Leu$^9$]-bradykinin, a bradykinin B$_1$ receptor antagonist, did not affect nitric oxide production by bradykinin, it enhanced the inhibition of endothelin-1 secretion by bradykinin. Furthermore, $10^{-7}$ M des-Arg$^9$-bradykinin, a bradykinin B$_1$ receptor agonist, stimulated endothelin-1 secretion by endothelial cells. These findings suggest that angiotensin I converting enzyme inhibitor inhibits endothelin-1 secretion by the accumulation of endogenous bradykinin in endothelial cells and that the inhibition of endothelin-1 secretion by bradykinin is mediated via B$_1$ receptors.

Key Words • angiotensin converting enzyme inhibitors • bradykinin • endothelin-1 • nitric oxide • endothelium

Endothelin-1 (ET-1) is a recently discovered endothelium-derived vasoconstrictive peptide. ET-1 induces a strong and sustained pressor response in vessels and systemic hypertension in the rat. It also stimulates mitogenesis in vascular smooth muscle cells. These studies suggest the potential importance of endothelin in the pathophysiology of hypertension and atherosclerosis. Angiotensin I converting enzyme (ACE) inhibitors generally have been used as antihypertensive drugs. However, the precise mechanism of the antihypertensive effects of ACE inhibitors has not been fully elucidated. In addition, there is recent evidence for new important functions of ACE inhibitors in the cardiovascular field. ACE inhibitors can induce regression of intimal hyperplasia, whereas other antihypertensive drugs are ineffective in this regard. Clinical trials in patients with chronic congestive heart failure demonstrated a significant reduction in mortality with ACE inhibitor therapy. Although ACE inhibition diminishes the formation of a pressor peptide, angiotensin II, it also diminishes degradation of kinins, which are vasodepressor peptides. Bradykinin stimulates the synthesis of prostaglandin I$_2$ and endothelium-derived relaxing factor, recently identified as nitric oxide (NO). NO not only antagonizes the effects of ET-1 of vasoconstriction and mitogenesis of vascular smooth muscle cells but also inhibits the production of ET-1 by endothelial cells. Furthermore, ACE inhibitors stimulate the production of NO and prostaglandin I$_2$ mediated by B$_2$ receptors in endothelial cells. The present study therefore was performed to examine whether ACE inhibitor inhibits ET-1 secretion through the activation of B$_1$ receptors in endothelial cells.

Methods

Materials

Captopril, an ACE inhibitor, was donated by Sankyo Co., Tokyo. Bradykinin, d-Arg, [Hyp$^3$,Thi$^3$,D-Phe$^7$]-bradykinin, des-Arg$^9$-[Leu$^9$]-bradykinin, des-Arg$^9$-bradykinin, and $N^\circ$-nitro-L-arginine (L-NA) were purchased from the Peptide Institute, Osaka, Japan. Nitrate reductase was from Sigma Chemical Co., St. Louis, Mo. Other reagents were of the highest grade available.

Cells

Endothelial cells, isolated from human thoracic aortas, were purchased from Kurabo, Osaka, Japan, and cultured on collagen-coated dishes in modified MCDB 131 medium supplemented with 10% fetal calf serum at 37°C under 5% CO$_2$ in air. Cells at passages between 5 and 8 were used for the experiments and seeded at a density of $2 \times 10^4$ per well on collagen-coated 24-well plates.

Assay of Endothelin-1

Confluent cells were incubated for 24 hours in serum-free medium containing drugs or vehicle. After incuba-
FIGURE 1. Line graph shows dose-dependent effects of bradykinin (BK) on endothelin-1 (ET-1) secretion by endothelial cells. Cells were incubated with serum-free medium containing BK at concentrations indicated for 24 hours in presence (closed triangles) or absence (closed circles) of $3 \times 10^{-7}$ M $N^\circ$-nitro-L-arginine (L-NA). Values are mean±SEM (n=6). *p<0.05, significantly different from control; +p<0.05, significantly different from endothelial cells treated without L-NA.

Nitrite and Nitrate Assay
Confluent cultures of cells in 24-well plates were preincubated with serum-free modified MCDB 131 medium with or without various agents for 24 hours. Nitrite plus nitrate concentration was determined after treatment of 0.1 mL supernatant with nitrate reductase. Nitrite concentration (NO$_2^-$ plus NO$_3^-$ reduced to NO$_2^-$) in the samples was determined with Greiss reagents.

Statistical Analysis
Statistical analysis was performed by one-way analysis of variance. Results are expressed as mean±SEM. A value of p<0.05 was considered significant.

Results
After 24 hours of incubation of endothelial cells with serum-free medium, ET-1 concentration in the control culture was $1,321 \pm 42$ pg/mg cell protein (n=6). Treatment of endothelial cells with bradykinin at concentrations from $10^{-7}$ to $10^{-5}$ M significantly inhibited this basal secretion of ET-1 (Figure 1). This inhibition by bradykinin was partially reversed by coincubation with $3 \times 10^{-5}$ M L-NA, an inhibitor of NO synthesis, at a higher concentration than that of L-arginine in the medium ($3 \times 10^{-4}$ M).

Incubation of endothelial cells with captopril at concentrations of $10^{-8}$ and $10^{-7}$ M significantly suppressed ET-1 secretion to the same degree as incubation with bradykinin (Figure 2). Coincubation with $3 \times 10^{-7}$ M L-NA partially reversed this suppression by captopril of the endothelial cells. On the other hand, in the presence of $10^{-6}$ M Trp-Thr-Phe-Bradykinin, a B$_2$ receptor agonist, $10^{-7}$ M captopril did not inhibit but rather stimulated ET-1 secretion (Figure 3).

Although $10^{-7}$ M bradykinin inhibited ET-1 secretion, this inhibition by bradykinin was significantly enhanced by L-NA.
participation of bradykinin or NO in the cellular mechanism of this inhibitory effect of ACE inhibitors. ACE inhibition decreases not only formation of angiotensin II but also degradation of kinins. In cultured human and bovine endothelial cells, ACE inhibitors elevate intracellular calcium concentrations and stimulate the production of NO and prostaglandin I₂ via B₂ receptors. In the present study, the enhancement of NO production by captopril was inhibited by coincubation with the B₂ receptor antagonist. In addition, our preliminary experiments revealed that the concentration of bradykinin in the medium, determined by a specific radioimmunoassay kit (Otsuka Pharmaceutical Co. Ltd.), increased from 0.08±0.01 to 3.17±0.14 ng/mL (mean±SEM, n=6) after 24 hours of incubation of endothelial cells with 10⁻⁷ M captopril. Although the medium concentration of bradykinin in 10⁻⁷ M captopril-treated cells was lower than that of exogenous bradykinin, which inhibited ET-1 secretion to the same degree as incubation with 10⁻⁷ M captopril, it has been reported that inhibition of bradykinin degradation by captopril potentiates the vasodilator effect of bradykinin in rat mesenteric arteries. Furthermore, ACE inhibition by ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Therefore, accumulation of endogenous bradykinin by the inhibition of bradykinin degradation could be responsible for the inhibition of ET-1 secretion by captopril from endothelial cells.

Bradykinin, produced from kininogen by the action of kallikrein, has a variety of physiological and pharmacological effects on the vascular system; physiologically it induces endothelium-dependent relaxation of arteries. However, it also induces contraction of arteries and veins. These different effects of bradykinin on arteries have been explained by the existence of bradykinin receptor subtypes. Endothelial cells possess low-affinity B₁ receptors and high-affinity B₂ receptors. In this study, bradykinin-induced stimulation of NO production was inhibited by the B₂ receptor antagonist but not by the B₁ receptor antagonist. Because bradykinin-induced suppression of ET-1 secretion was reversed by L-NA, enhancement of NO production via the B₂ receptor may participate in the suppression of ET-1 secretion by bradykinin. In contrast, coincubation with B₁ receptor antagonist did not reverse but rather enhanced the bradykinin-induced suppression of ET-1 secretion. Furthermore, the B₂ receptor antagonist did not affect NO production but significantly stimulated ET-1 secretion by the endothelial cells. Thus, although bradykinin physiologically inhibits ET-1 secretion by enhancing NO production via B₂ receptors, bradykinin can stimulate ET-1 secretion when B₂ receptor pathways are more activated than B₁ receptor pathways in endothelial cells. In addition, the enhancement of NO production by captopril was inhibited by B₂ receptor antagonist but not by B₁ receptor antagonist. Furthermore, although captopril alone inhibited the secretion of ET-1, it stimulated ET-1 secretion when captopril-induced enhancement of NO production was inhibited by coincubation with B₂ receptor antagonist. These results suggest that captopril suppresses ET-1 secretion by the accumulation of endogenous bradykinin in endothelial cells under physiological conditions. However, captopril can stimulate ET-1 secretion under pathological conditions in which endothelial cells possess predominantly B₁ receptors rather than B₂ receptors.

**Figure 4.** Bar graph shows effects of bradykinin (BK) receptor antagonists on nitric oxide (NO) production induced by BK or captopril. Cells were incubated with assay medium containing 10⁻⁷ M BK, 10⁻⁷ M des-Arg⁵-BK (BK agonist, a B₁ receptor agonist), or 10⁻⁷ M captopril. Des-Arg⁵-[Leu⁶]-BK (10⁻⁶ M) (a BK receptor antagonist [RAL]) or des-Arg⁵-[Hyp⁴,Thr⁶,Phe⁷]-BK (10⁻⁶ M) (a B₂ receptor antagonist) was co-incubated with BK or captopril. Values are mean±SEM (n=6). *p<0.05, significantly different from control; +p<0.05, significantly different from BK or captopril in the absence of B₁ receptor antagonist.

**Discussion**

The present study demonstrates that the ACE inhibitor captopril inhibits the basal secretion of ET-1 by vascular endothelial cells. Coincubation with L-NA, an inhibitor of NO synthesis, reversed the inhibition by captopril. Furthermore, captopril actually enhanced NO synthesis in endothelial cells, suggesting that NO participates in this inhibition of ET-1 secretion by captopril.

Recently, Yoshida and Nakamura also reported that ACE inhibitors inhibit 5% calf serum-stimulated ET-1 secretion but not the basal secretion of ET-1 by endothelial cells. However, they did not consider the participation of bradykinin or NO in the cellular mechanism of this inhibitory effect of ACE inhibitors. ACE inhibition decreases not only formation of angiotensin II but also degradation of kinins.
Acknowledgments
We are grateful to Taeko Kaimoto for technical assistance and Chiaki Murakami for secretarial work.

References
Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin.
N Momose, K Fukuo, S Morimoto and T Ogihara

Hypertension. 1993;21:921-924
doi: 10.1161/01.HYP.21.6.921

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1993 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/21/6_Pt_2/921

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/